← ANALYST RATINGS · TIPRANKS
Praxis Precision Medicines (PRAX): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy0 Hold0 Sell
Ratings of 12 analysts in the last 3 months · top analysts only12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $742, the highest $1,201, the lowest $462. The average is +207.0% from the last price of $242.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $700 | Buy | +189.5% | Initiated | 15.10.26on TipRanks 16:35 | −1.5% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $1,201 | Buy | +396.8% | Reiterated | 15.10.26on TipRanks 07:15 | +3.6%next day −1.5% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $706 | Buy | +192.0% | Initiated | 14.10.26on TipRanks 19:50 | +3.6%next day −1.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $285 → $268−6.0% | Hold | +10.9% | Reiterated | 13.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $282 → $255−9.6% | Hold | +5.5% | Reiterated | 13.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $285 → $258−9.5% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $275 → $254−7.6% | Hold | +5.1% | Reiterated | 13.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $283 → $263−7.1% | Hold | +8.8% | Reiterated | 13.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $297 → $267−10.1% | Hold | +10.4% | Reiterated | 09.10.26on TipRanks 05:05 | — | |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $810 → $826+2.0% | Buy | +241.7% | Assigned | 06.10.26on TipRanks 06:50 | −1.8%next day −0.5% · 5 days −13.0% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $441 → $534+21.1% | Buy | +120.9% | Reiterated | 01.10.26on TipRanks 16:35 | +2.3%next day −4.7% · 5 days −13.2% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $582 | Buy | +140.7% | Reiterated | 24.09.26on TipRanks 05:55 | 0.0%next day −0.9% · 5 days +2.2% | ↗ |
| Kevin Strang★★★★★★★★★★#10513 · hits 33% · avg −19.6% | Goldman Sachs | $470 → $575+22.3% | Buy | +137.8% | Assigned | 21.08.26on TipRanks Aug 20 07:30 | −4.8%next day +2.7% · 5 days −0.2% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $650 | Buy | +168.9% | Reiterated | 17.08.26on TipRanks Aug 18 05:55 | +3.1%next day −1.1% · 5 days −1.0% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $765 → $945+23.5% | Buy | +290.9% | Reiterated | 17.08.26on TipRanks 09:25 | +3.1%next day −1.1% · 5 days −1.0% | ↗ |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $754 | Buy | +211.9% | Assigned | 08.08.26on TipRanks Aug 6 14:10 | +16.1%next day −3.1% · 5 days −1.7% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $1,200 | Buy | +396.4% | Reiterated | 07.08.26on TipRanks 11:27 | −3.1%next day +1.7% · 5 days +1.3% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $400 → $514+28.5% | Buy | +112.6% | Reiterated | 07.08.26on TipRanks 08:10 | −3.1%next day +1.7% · 5 days +1.3% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $616 | Buy | +154.8% | Reiterated | 07.08.26on TipRanks 08:01 | −3.1%next day +1.7% · 5 days +1.3% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $323 → $362+12.1% | Hold | +49.7% | Reiterated | 07.08.26on TipRanks 07:06 | −3.1%next day +1.7% · 5 days +1.3% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $800 | Buy | +230.9% | Reiterated | 06.08.26on TipRanks Aug 7 08:01 | +16.1%next day −3.1% · 5 days −1.7% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $449 → $462+2.9% | Buy | +91.1% | Assigned | 06.08.26on TipRanks Aug 7 07:06 | +16.1%next day −3.1% · 5 days −1.7% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $510 | Buy | +111.0% | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +16.1%next day −3.1% · 5 days −1.7% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $550 | Buy | +127.5% | Reiterated | 30.06.26on TipRanks 08:45 | −5.3%next day −4.4% · 5 days −0.4% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $166 → $162−2.4% | Sell | −33.0% | Reiterated | 02.06.26on TipRanks 07:55 | −23.1%next day +8.8% · 5 days 0.0% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $420 → $374−11.0% | Buy | +54.7% | Reiterated | 02.06.26on TipRanks 04:35 | −23.1%next day +8.8% · 5 days 0.0% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $500 | Buy | +106.8% | Reiterated | 06.04.26on TipRanks Apr 7 08:15 | −0.6%next day −1.1% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Praxis Precision Medicines
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $693 at a price of $291 (+138.0%); now: $702 at $242 (+190.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 29 | 24 | 24 | 10 | 14 |
| Buy | 6 | 9 | 6 | 7 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 2 | 2 | 1 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-3.54 (from $-4.23 to $-2.74). Last quarter: $-2.87.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Praxis Precision Medicines
- CEO: Marcio Silva De'Souza
- Employees: 168
- 99 High Street, Boston, MA, 02110, US
- www.praxismedicines.com
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗